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THERE MAY BE A GENETIC PREDISPOSITION to the development of irritable bowel syndrome (IBS), based on studies demonstrating associations of genetic variation in patients with IBS with symptom phenotype and intermediate phenotypes or quantitative traits (predominantly colonic transit, reviewed in Ref. 7) as well as studies of mRNA expression in rectal and colonic mucosa in patients with IBS (1). Significant associations (6) are reported between IBS phenotypes and genetic variations in mucosal immunity or susceptibility to inflammation (e.g., TNFSF15, TLR 9) , barrier function (e.g., PRDM1), protective biochemical processes against luminal microorganisms (e.g., mucosal expression of oxidases), bile acid homeostasis [e.g., Klotho ␤ (KLB) rs17618244 and fibroblast growth factor receptor 4 (FGFR4) rs1966265 and rs351855], as well as expression of neurotransmitters and cytokines, such as cannabinoid (e.g., FAAH, and CNR1) and adrenergic (e.g., ␣2C) receptors, and serotonin transporter (SLC6A4).
Candidate genes controlling KLB and FGFR4 proteins are associated with colonic transit in diarrhea-predominant IBS (IBS-D), the response of colonic transit to the bile acid (BA) sequestrant colesevelam in IBS-D, and the colonic transit and stool responses to chenodeoxycholic acid in patients with constipation-predominant IBS (IBS-C) (28, 42, 43) . About 25% of patients with IBS-D have evidence of increased BA synthesis or excretion (41) . Two other genes involved in BA function are liver receptor homolog-1 (LRH1), which is involved in bile acid homeostasis, and fatty acid binding protein 6 (FABP6), which is required for efficient absorption and transport of bile acids. We have previously reported on associations of the bile acid receptor gene, TGR5 (GpBAR1) single nucleotide polymorphism (SNP) rs11554825 [minor allele frequency (MAF) 41%], with small bowel and colonic transit (11) . We included TGR5 in this study in assessing association with IBS-D but excluded it from the analysis of genetics of BA uptake, synthesis, and homeostasis.
Whereas genomewide association studies (GWAS) have identified genetic markers associated with common diseases, (22) , there have been no GWAS pertinent to the common gastrointestinal disorder IBS. For meaningful GWAS, it was recommended that there should be accurate phenotype assessment and building of pathway/network models to link inherited and acquired variation together in a unified framework (22) .
We have previously documented colonic transit by scintigraphy as a biomarker of colonic function in IBS (9) and used it extensively in genotype-intermediate phenotype studies in the last decade. BA malabsorption in patients with functional diarrhea and IBS-D is identified by measurement of BA synthesis, BA retention, or fecal BA excretion (10, 13, 15, 31, 36 -38, 40, 41) .
The aims of the present study were, first, to mine the exome DNA in genes reported to be associated with dysfunctions in IBS-D in published literature, and second, to mine the complete exome to identify putative rare single nucleotide variants (SNVs) associated with irritable bowel syndrome-diarrhea (IBS-D) phenotype. For these first two aims, DNA from 16 IBS-D patients was extracted and analyzed by exome-capture and next-generation sequencing. The data analysis was stratified to initially focus on a candidate list of genes previously associated with IBS or its treatment (selected from a review of the literature) and, as a second step, to discover rare, putatively functional variants with a phenotype association in the remaining exome.
In a third aim, we assessed the complete exome of genes that regulate BA absorption, feedback regulation, and synthesis in IBS-D in two groups of patients with increased fecal BAs (32) , selected on the basis of a principal components analysis: one group with rapid colonic transit and "passive" increase in fecal bile acid excretion; and a second group of patients who have increased synthesis of bile acids, as might occur as a result of reduced FGF-19 feedback regulation, in accordance with the data published by Walters et al. (37) and confirmed in a prior study from our laboratory (28) . The analysis was then extended to evaluate the univariate association of identified genetic mutations with the established phenotypes and principal component subgroups. Significant findings from this analysis were validated in the fourth aim in a separate cohort of participants previously characterized in our laboratory in whom we explored univariate associations of SNVs of interest, identified by the exome analysis of BA-related genes, with symptoms phenotype (n ϭ 633 IBS or healthy controls) and colonic transit (n ϭ 141 IBS).
METHODS
Study design, participants, and ethical review for exome sequencing study. Our study design was based on the evaluation of detailed genetic associations in 16 patients with IBS-D. We chose to focus on IBS-D patients rather than the whole spectrum of phenotypes and the diverse underlying mechanisms in IBS patients across the spectrum, some having constipation or alternating bowel function. It is estimated that ϳ25% of IBS-D is associated with increased BA synthesis or excretion. These patients had participated in a prior study that included a total of 22 patients with IBS-D who had undergone studies of bile acid homeostasis [altered BA feedback regulation (serum FGF-19), hepatic synthesis (serum C4; 7␣-hydroxy-4-cholesten-3-one), and fecal BA excretion (fecal BA)] and colonic transit (41) . Thus, to explore the mechanisms causing alterations in BA synthesis or excretion, we first conducted a principal components analysis to identify two cohorts, each consisting of eight patients, in whom the increased fecal BA excretion was associated with either accelerated colonic transit or increased hepatic synthesis (serum C4).
Principal components analysis. We have recently shown that there are independent contributions of colonic transit and fecal bile acids to stool form and number (32) ; in addition, fecal BA may be increased as a result of increased hepatic BA synthesis. However, the previously reported significant correlation between serum C4 and fecal BA excretion [r s ϭ 0.606, P Ͻ 0.001 (41) ] showed that increased synthesis accounts for Ͻ40% in the variance of fecal BA. Another cause of increased fecal BA excretion is accelerated intestinal transit (30) or colonic transit at 48 h [r s ϭ 0.41, P Ͻ 0.01 (32) ]. Therefore, it is possible for patients with IBS-D to have elevated fecal bile acids as a result of at least two mechanisms: accelerated transit or increased bile acid synthesis. To explore the potential genetic mechanisms involved in IBS-D that may operate by altering bile acid control mechanisms, it was therefore important to identify patient cohorts that reflected a phenotype of accelerated transit or increased bile acid synthesis, even though both groups had increased fecal bile acids.
To achieve this goal, we used a principal component analysis that identifies linear combinations of the pathophysiological variables (29) , which are weighted ("loading factor") sums of the variables to be considered together when more than one mechanism is conceivably responsible for the phenotype, specifically IBS-D. Each linear combination is chosen to explain the most between-persons variation subject to the constraint that they are not correlated with other combinations. Thus the first principal component score (or PC1) was a weighted linear combination of the four variables in transit and bile acid homeostasis (serum FGF-19, serum C4, stool BA) that accounted for the maximum between-persons variation. The weight (loading) for a specific variable is the coefficient multiplier used for that variable in the given principal component score. The second linear combination (PC2) explained the maximum possible remaining variation and was not correlated with PC1. A third principal component was identified after the study. Ultimately, a total of three principal component scores were assessed (including two a priori selected principal component scores). These three principal components accounted for ϳ92% of the total between subjects variation in the four variables.
Subgroup 1 had fast colonic transit [24-h geometric center (GC24)], high serum FGF-19, moderate fecal BA, and low serum C4. This cohort was selected to reflect low likelihood of the phenotype being secondary to excess BA synthesis.
Subgroup 2 was characterized by moderate colonic GC24, moderate levels of FGF-19, and high fecal BA and serum C4, which collectively reflect greater likelihood of BA excess synthesis or malabsorption. The characteristics of these two groups appear in Table 1 .
Intermediate phenotypes (or quantitative traits) were characterized for the 16 patients identified, DNA availability confirmed, and research authorization for use of DNA and medical records obtained from the Mayo Clinic Institutional Review Board.
Exome and in-depth DNA sequencing method and bioinformatics analysis. Patient DNA was captured by using Agilent SureSelectXT All Exome V4 and sequenced by multiplexing four samples per lane on an Illumina HiSeq 2000. The resulting data were analyzed by using an internally developed next-generation sequencing workflow consist- ing of three steps: alignment, single nucleotide and small insertion/ deletion variant calling, and annotation. FASTQ files were aligned to the hg19 reference genome by using Novoalign (VN:V2.07.13; www.novocraft.com) with the following options: -hdrhd off -v 120 -c 4 -i PE 425,80 -x 5 -r Random. Realignment and recalibration was performed by use of GATK (VN:1.6 -7-g2be5704) (21) Best Practices version 3. Germline variations were called with GATK's UnifiedGenotyper using default parameters. Variant quality score recalibration is also done with the following command line optimizations: for SNVs, -an QD -an HaplotypeScore -an MQRankSum -an ReadPosRankSum -an FS -an MQ -an DP -nt 2 -maxGaussians 4 -percent BadVariants 0.05; and for insertions or deletions of bases in the DNA (INDELs), -an QD -an FS -an HaplotypeScore -an ReadPosRankSum -maxGaussians 4 -nt 2 -percentBadVariants 0.12 -std 10.0. VQSR "PASS" filter variants were selected for further analysis. VCF files were subsequently annotated by using Mayo Clinic's BioR annotation repository, which includes variant population frequencies (HapMap, 1k Genomes, ESP6500), frequency of occurrence in 50 internal-toMayo control samples, and function predictions of variant effects with SNP-Eff (effects of SNPs) (12) and SIFT (Sorting Intolerant from Tolerant) (26) . "High-impact" variants identified by SNP-Eff were selected for further analysis and consisted of coding variants that affect canonical splice site acceptors and donors, disrupt start sites, cause frame shifts, and disrupt or induce stop codons.
The 50 control samples were used to identify and exclude variants with discontinuity between the reported population-wide frequency and the observed internal-to-Mayo frequency; these variants have a high likelihood of being false positive arising from local analytical pipeline bias. These samples were captured with Agilent SureSelect All Exome V4 ϩ UTR and sequenced to an average depth of 120 million reads per sample on an Illumina Hiseq2000. The samples were obtained from Mayo Clinic's BioBank and consisted of deceased individuals with confirmed cause of death.
Targeted analysis of exome data in genes associated with bile acid and IBS. The candidate list was extracted from information found in the literature and includes genes associated with IBS or its treatment. The list included genes with function related to drug metabolism, receptors of neurotransmitters or hormones, an alternative bile acid receptor (TGR5 or GPBAR1), and cytokines and inflammatory mediators ( Table 2 ). All variants identified within these genes were reported for further consideration. 
Association of whole exome and IBS-D phenotype.
The complete exome was analyzed to identify rare variants with potentially damaging effect on the encoded protein that might be associated with the IBS-D phenotype. Results were filtered to select for nonsynonymous variants and exclude all variants with a reported MAF Ͼ2% in any population dataset from HapMap, 1k Genomes, as well as the ESP4500. The results were subsequently annotated with the SIFT prediction for functional impact.
Association of genetic variations in bile acid genes. To investigate possible molecular differences in IBS-D symptom phenotype subsets, a list of 11 genes associated with bile acid homeostasis was created from the established pathway for bile acid synthesis (Fig. 1 ). This list included ASBT (SLC10A2), FXR (NR1H4), OST␣/␤ (SLC51A/B), FGF19, FGFR4, KLB, SHP (NROB2), CYP7A1, as well as LRH1 (also known as NR5A2 or nuclear receptor subfamily 5, group A, member 2), which is involved in bile acid homeostasis and steroidogenesis, and FABP6, which is required for efficient absorption and transport of bile acids in the distal portion of the murine small intestine (27) , but a prior study concluded that most cases of primary BA malabsorption are unlikely to be caused by genetic variation in FABP6 (3). All variants identified within these genes were reported for further consideration.
Association of SNVs of interest in KLB and FGFR4 in a larger cohort of IBS and controls.
After identifying three SNVs that had different prevalence in the IBS-D patients than the controls or were univariately associated with one or more of the principal components, we validated these findings by interrogating our database of 633 people (405 IBS patients and 228 controls), as described elsewhere (8 We included intron FGFR4 rs434434 because we noted that the proportion of IBS-D patients with this allele (15/16) far exceeded the reported frequency of this allele in HapMap (CEU) of 0.21. Genotyping of KLB (rs1015450) and FGFR4 (rs434434, rs1966265, and rs351855) was performed with TaqMan SNP Genotyping Assays (Life Technologies, Grand Island, NY) according to the manufacturer's instructions using 10 -20 ng of genomic DNA for each sample. Following polymerase chain reaction (PCR) amplification, end reactions were read on the 7300 Real-Time PCR System by use of Sequence Detection Software.
Statistical analysis. We assessed the univariate associations of each SNV with colonic transit, fecal BA, serum FGF-19, serum C4, and two subgroups based on the first two principal components from a principal components analysis selected a priori. The associations with a third principal component obtained in the principal components analysis were also assessed post hoc. In the separate set of data from previous studies, the association of symptom phenotype (IBS subtype vs. health) with four selected SNVs was assessed by the 2 test (general genetic model) and, for colonic transit quantitative trait (in IBS-C and IBS-D), by the Wilcoxon rank sum test (dominant genetic model).
RESULTS

Organization of results section.
The results are organized in the following sections: first, we present demographics of 16 participants whose DNA was sequenced in depth, and a highlevel review of the exome-sequencing data; second, we address the first aim (to mine the complete exome to identify putative SNVs associated with IBS-D phenotype) through an in-depth analysis of SNVs previously reported in association with IBS and its treatment, followed by a mining of the remaining exome for rare, putatively functional variants associated with IBS-D; third, we analyze the association of SNVs identified by in-depth DNA sequencing with principal component subgroups based on quantitative traits of colonic transit, fecal BA excretion, and principal component groups; fourth, we assess the symptom phenotypes and colonic transit in association with Demographics of participants. The age, gender distribution, body mass index, quantitative transit, and bile acid parameters of patients in the two subgroups designated according to the principal components analysis are shown in Table 1 .
Exome-sequencing data. The 16 IBS-D samples were sequenced with 100 base paired-end reads, multiplexed four to a lane, on an Illumina HiSeq2000. An average of 104 million reads per sample were generated, with 97.9% mapping to the reference genome, resulting in greater than 90% of the exomecapture region covered by at least 30 reads. There were 40,957 SNVs identified on average, per sample. An average of 145 variants computationally classified as "High Impact," potentially detrimental to the encoded protein, were identified per sample, including five novel (as defined by the absence of an associated dbSNP135 entry) variants.
Associations of literature-reported genetic variations in IBS with the present cohort. Forty-five of 50 genes identified from the literature as associated with IBS or its treatment carried at least one SNV in our 16 IBS-D samples. In total, there were 189 position-unique SNVs identified, of which 74 were nonsynonymous changes. We used a permissive MAF filter (20%) to exclude extremely common mutations from further consideration. The frequency filter was based on a level twice the reported global community-based prevalence of IBS of 11.2%, 95% CI 9.8 -12.8% (20) . The 39 nonsynonymous mutations that passed the MAF filter are summarized in Table 2 and show the frequency of IBS-D subjects and control samples carrying each mutation. There was no difference in the proportion of IBS-D subjects and controls with these 39 nonsynonymous mutations, as shown in Table 2 .
There were also 21 position-unique INDELs identified in the target genes, of which 3 caused frame shift mutations (Table  2) . A G deletion in HTR3E (HTR3E 5-hydroxytryptamine receptor 3E) was found in three samples, a C insertion in NOD2 (nucleotide-binding oligomerization domain containing 2) was found in a single sample, and a TT insertion in CARD8 was found in another single sample. All three frame shift INDELs appeared to be heterozygous mutations. The HTR3E and CARD8 (caspase recruitment domain family, member 8) INDELs were identified at comparable frequencies in the 50 control samples, whereas the NOD2 insertion was not identified in any control sample.
Rare functional variants in association with IBS-D. In addition to the candidate gene query, we also surveyed the remaining exome for possibly variants of interest. Given epidemiological data suggesting a pooled prevalence of IBS-D among women with IBS of 31% [95% CI 22-41% (19) ], the most conservative estimate of IBS-D would be 22% of 9.8%, that is, ϳ2%. Results were filtered to identify putatively functional, rare variants associated with the IBS-D phenotype, by selecting variants with an associated minor-allele-frequency Ͻ5%, found in Ͻ20% of the control samples, and annotated as High Impact by SNP Effect Predictor. High-impact classified mutations include changes impacting splice sites (acceptor and donor motifs), loss of a start site, and gain or loss of stop sites. A total of 210 variants meeting these criteria were found across the 16 samples. One hundred and ninety of these variants were unique private mutations (found in 1/16 samples analyzed). Of the remaining, 16 variants were found in 2/16 samples and 3 in 3/16 samples. Three of the variants found in 3/16 samples were enriched in the IBS-D samples compared with the control samples. All variants found in more than one sample are listed in Appendix Table A1 .
Additionally Table A1 ).
We identified 19 SNVs that were absent in the 50 controls and were identified in at least 2 of the 16 patients: ASB15, ATP13A5, ATP2C2, C15orf48, C6orf203, CCDC138, CTBP2, CYB5R2, EIF5B, FADS6 (two SNVs), KRTAP10 -7, MICA, MMP1, OR2T35, OR2T4, XAF1, ZNF626, and ZNF717. The full names of the genes and the potential specific mechanisms that might be related to IBS, based on literature reports on the genes, are listed in Appendix Table A2 .
Interestingly, a 57-base deletion in keratin-associated protein 4 -1 (KRTAP4 -1) was identified in 15 samples and only 3 of the control samples. However, this deletion leads to the loss of an intron region between exons 1 and 2 but does not impact the coding sequence.
Principal component identification. As shown in Fig. 2 , the four selected quantitative parameters were able to identify two preselected groups, each consisting of eight patients: those with fast colonic transit/moderate BA excretion, and those with high BA excretion. Figure 2 clearly shows the separation of the two groups of patients; one patient was included in principal components analysis subgroup 1 based on very rapid colonic transit with normal serum C4. The analysis of the entire 16 patients also identified a third principal component (designated in Table 3 as PC3). This component was positively associated with FGF-19 (r ϭ 0.58, P ϭ 0.02) and inversely correlated with colonic transit GC24 (r ϭ Ϫ0.53, P ϭ 0.03). Gene variants associated with colonic transit, fecal BA, and principal components. Genetic variations in KLB and FGFR4 (but not FGF-19, ASBT, FXR, SHP, or CYP7A1) were associated with colonic transit, fecal BA, and two subgroups based on a principal components analysis (Table 3 ). It is noteworthy that, among these SNVs, one appeared to be more frequently present [KLB (rs1015450)] and one somewhat less prevalent (FGFR4 rs351855) in the 16 IBS-D patients than in the 50 controls. In addition FGFR4 rs434434 was identified in 15/16 IBS-D patients, and this frequency was much higher than the 0.21 frequency reported in HapMap CEU; however, it was also found in 49/50 control samples. The KLB variant (rs1015450) was associated with fecal BA excretion, FGFR4 rs1966265 was associated with increased colonic transit or the principal components, and FGFR4 rs434434 was associated with principal components subgroup. On the other hand, FGFR4 rs351855 was associated with both colonic transit (GC24) and with the third principal component (a quantitative score related to decreased BA synthesis and relatively slower colonic transit).
The symptom and colonic transit phenotypes in association with SNVs of interest in FGFR4 and KLB in a larger cohort of IBS-D and IBS-C are detailed in Tables 4 and 5 and discussed more extensively below.
Mutation data for the 11 genes in the bile acid pathways. We found a total of 55 single-nucleotide variations in 10 of the 11 genes involved in BA homeostasis [including LRH-1 and FABP6 (Table 6 )], with no SNVs identified in the 11th gene, FGF19. The variations were annotated with the frequency observed in 50 control samples of similar ethnicity. There were 15/55 variations that were observed in less than 20% of the control samples. Sixteen SNVs were nonsynonymous, including coding variations in SHP(NROB2) (rs6659176), KLB (rs17618244, rs35372803, rs4975017), ASBT (SLC10A2) (rs71640248, rs188096, rs60380298, and a rare variant at chr13:103710656 A¡G), FGFR4 (rs1966265, rs376618, rs351855, rs442856), OST␣ (rs939885, rs7642243), and FABP6 (rs116237330 and rs1130435). There were no significant differences in proportions of these SNVs in IBS-D relative to normal controls; however, in addition to the significant associations with colonic transit (nonsynonymous FGFR4 rs1966265) or principal component (intron FGFR4 rs434434) discussed above in Table 3 , three nonsynonymous SNVs exhibited possible association with high vs. medium FGF-19 Associations are based on PC1 and PC2. The third principal component assessed posthoc is a quantitative score. PC groups are summarized as: PC1 fast colonic transit, PC2 increased bile acid synthesis diarrhea, and PC3 decreased bile acid synthesis (due to increased feedback regulation by FGF-19) with relatively slower colonic transit. *Kruskal-Wallis test and †Fisher's exact test: P values for test of association with SNV. †Principal component 3 was positively associated with (rank) FGF19 (r ϭ 0. 44, P ϭ 0.08) and negatively associated with (rank) GC24 (r ϭ Ϫ0.59, P ϭ 0.022). status. These were KLB rs17618244 [which was previously associated with accelerated transit in IBS overall and IBS-D (5 high BA excretion and 1 medium BA excretion)], KLB rs4975017 (2 high BA excretion and 5 medium BA excretion); and NROB2 (SHP) rs6659176 (0 high BA excretion and 3 medium BA excretion).
Other than FGFR4 rs434434 (intron) association with principal component group (Table 2) , the remaining 39 SNVs had unclear significance: 22 nongenic, 10 synonymous, 2 in the 5= untranslated region (UTR), and 5 in the 3= UTR. There were also 5 INDELs identified in these BA-associated genes. All five INDELs were located in noncoding regions and none of the INDELs showed enrichment in the two cohorts of patients with high BA vs. those with faster colonic transit and moderate BA excretion.
Associations of SNVs in FGFR4 and KLB with symptom phenotype or colonic transit in larger cohorts of IBS and health.
Given the univariate associations of four SNVs in KLB (rs1015450) and FGFR4 (rs434434, rs1966265, rs351855) with colonic transit, BA quantitative traits, or principal components group (Table 3) , we analyzed the associations of these genetic variants with IBS symptom phenotype (633 total participants) and colonic transit in 141 patients with IBS. The percentages of patients in each of the symptom phenotypes in association with the four SNVs are shown in Table 4 .
FGFR4 rs434434 is intronic and is likely in linkage disequilibrium (r 2 ϭ 0.781) with rs376618. In our prior study, we detected that rs376618 was not in Hardy-Weinberg equilibrium (P ϭ 0.048) (8) , and, in the present study, it was present in similar proportions in IBS-D (15/16) and controls (49/50).
However, rs434434 was associated with symptom phenotype in the 633 participants (P ϭ 0.027), but not with colonic transit at 24 h (P ϭ 0.78) and 48 h (P ϭ 0.89), based on the 141 patients with colonic transit measured in IBS-C or IBS-D (Table 5) .
FGFR4 rs351855 was previously identified as a characteristic involved significantly with KLB rs17618244, which was associated with colonic transit at 24 h in the IBS-D subgroup (8) . In the present study, rs351855 was not significantly associated with symptom phenotype (P ϭ 0.30), and there was not an association with colonic transit at 24 h (P ϭ 0.81) and at 48 h (P ϭ 0.76).
FGFR4 rs1966265 was previously identified as a significant characteristic involved with KLB rs17618244, which was associated with colonic transit (GC24) in the IBS-D subgroup (8) . In the present study, rs1966265 was not significantly associated with symptom phenotype (P ϭ 0.70), but there was a modest association with colonic transit at 24 h (P ϭ 0.066), less evident at 48 h (P ϭ 0.256).
KLB (rs1015450) was not significantly associated with symptom phenotype (P ϭ 0.40) or colonic transit at 24 h (P ϭ 0.85) and at 48 h (P ϭ 0.98).
KLB (rs17618244) was not significantly associated with symptom phenotype (P ϭ 0.67), but, as in our prior study (43) , there was significant association with colonic transit. Specifically, we identified association of rs17618244 with colonic transit (Table 5) at both 24 h (P ϭ 0.005) and 48 h (P ϭ 0.034) in the combined IBS-C and IBS-D subtypes (based on KruskalWallis test).
DISCUSSION
There are several observations pertaining to the main aims of the present study.
Mining genetic mechanisms putatively involved in the control of dysfunctions in IBS-D.
Our analysis explored variants in the main putative mechanisms involved in the control of dysfunctions in IBS-D, specifically receptors of neurotransmitters or hormones (e.g., 5-HT and 5-HT 3 receptors), and cytokines or inflammatory factors (e.g., IL-6, TNF-␣). The nonsynonymous SNVs in the 45 genes (Table 2) were also similarly distributed in the IBS-D and 50 controls, and these included the SNVs in GPBAR1, the gene controlling the synthesis of TGR5 receptor protein.
Specifically, this analysis identified two variant-containing genes controlling 5-HT 3 receptors and IBS-D, although the prevalence in controls and IBS-D in the present study was not different. A G deletion in HTR3E was found in 3 of the 16 samples from IBS-D patients. This observation is consistent with a study of genetic variation of 5-HT 3 receptor genes in IBS patients from the United Kingdom and Germany (16) , which showed that the novel HTR3E 3=-UTR variant c.*76GϾA (rs62625044) was associated with D-IBS in female subjects. Using a reporter assay, Kapeller et al. (16) showed that gene variant affected the binding of miRNA-510 to the HTR3E 3=-UTR and caused elevated protein expression in two different cell lines.
Similarly, a SNV in the HTR3D gene was identified in 2 of 16 patients. It is relevant to note that 5-HT 3D receptors are expressed in both myenteric and submucosal neurons (17) and therefore conceivably alter secretory and motor functions in the intestines or conceivably the response to treatment with 5-HT 3 antagonists such as alosetron, which is efficacious for treatment of IBS-D (2) .
Mining the complete exome. Our study mining the complete exome identified a total of 118 candidate mutations of interest.
One candidate mutation of interest following a review of the literature was an SNV in ZNF77 (zinc finger protein 77) in 2 of Values are means Ϯ SD. Association of rs17618244 with both GC24 (P ϭ 0.005) and GC48 (P ϭ 0.034) in the combined IBS-C and IBS-D subtypes (based on the Kruskal-Wallis test). No significant associations were detected for rs434434.
16 patients was also found (compared to 2 of 50 controls). This mutation, causing a glutamine to stop codon change, has been shown to be significantly associated with fibromyalgia syndrome (14) ; a systematic review reported that 49% of fibromyalgia patients suffer IBS (39) . Overall, these data suggest a potential role for the disruption of this zinc finger protein in IBS.
There were four SNVs that may have biological effects that may be relevant to peripheral pathophysiological mechanisms associated with IBS (6) . A SNV in ATP2C2 [the gene encoding secretory pathway calcium-transporting ATPase, type2C, member2, which is a Golgi-localized pump with high affinity for Ca 2ϩ ions (34)] could affect motor, sensory, or secretory mechanisms. A second variant was located in XAF1 (X-linked inhibitor of apoptosis-associated factor 1) and annotated to induce a premature stop codon. A third SNV in MHC class I polypeptide-related sequence A (MICA) gene could impact immune processes that are relevant in the microscopic immune activation in some patients with IBS. A fourth SNV in MMP1 (matrix metallopeptidase 1) that encodes for an interstitial collagenase could conceivably impact colonic compliance or tone which may be relevant to IBS.
In addition to the direct associations reported through the literature above, potentially relevant functional associations are described for two additional genes harboring SNVs in 2 of 16 patients, each. ATP2C2 [the gene encoding secretory pathway calcium-transporting ATPase, type2C, member2, which is a Golgi-localized pump with high affinity for Ca 2ϩ ions (34)] was annotated as being in a splice site acceptor motif. The second variant was located in XAF1 and annotated to induce a premature stop codon. These are potentially relevant because the former influences intracellular calcium transport, which is involved in function of the enterocytes, muscle, and nerve function, whereas the latter influences apoptosis or autophagic cell death. However, there are no hitherto reported effects or associations with IBS. It is interesting to note that rats fed the secretory bile salts chenodeoxycholate and deoxycholate showed colonic mucosa histology with a significantly reduced apoptotic index (4). The relatively low prevalence (2/16 patients) suggests relevance in a small subgroup of IBS-D.
Case-control analysis of whole exome in two cohorts based on principal components. Our third approach in this study followed a case-control design, enhanced by a principal components analysis to compare two subgroups of patients with IBS-D, based on two pathophysiological mechanisms: accelerated transit [which was documented in 46% patients with IBS-D (9)] with moderate fecal BA excretion and a separate group with increased bile acid synthesis [by serum C4 in 9% patients with IBS-D (41)]. Although whole exome sequencing in complex disorders is typically applied to family-based studies with affected and nonaffected individuals, this approach is impractical in IBS in which data from familial aggregation and twin studies are conflicting (5) and their pathophysiological mechanisms of IBS-D are diverse (6) . Therefore, we perceive that genetic association studies in IBS are strengthened by robust identification of the quantitative phenotype of included participants.
In this analysis, we identified additional genetic variants in KLB and FGFR4 in association with fecal BA excretion or colonic transit in patients with IBS-D; SNVs in 8 of 9 other BA-related genes were not associated with these quantitative traits in IBS-D patients. These findings generally confirm our prior, candidate gene-based study that KLB and The FGF-19 deficiency might conceivably be due to genetic variations in the ileal enterocyte proteins that control its synthesis, such as SHP and FXR. We found several SNVs in these genes; however, we were not able to show an association with SNVs in the FGF-19 gene. Similarly, in the ASBT gene for the ileal BA transporter (SLC10A2), we identified 10 SNVs, seven of which were common polymorphisms (MAF Ͼ 1%), but none were associated with FGF-19 deficiency. The previous literature had shown no mutations in the ASBT gene for SLC10A2 in individuals or families of patients with idiopathic bile acid malabsorption (24, 25) .
Our study approach does not exclude the potential contribution of disorders at the levels of transcription or posttranscriptional modification to the development of the IBS-D phenotype or alterations in quantitative traits (transit and fecal BA excretion). In addition, future studies will also need to be directed at the expression of these proteins in tissues such as ileal mucosa or liver.
Association of KLB and FGFR4 with quantitative traits in the current and independent IBS cohorts. Our exome-based analysis identified SNVs in the genes for KLB and FGFR4 in association with the subgroups of patients and with fecal BA excretion or colonic transit. These data are summarized in Table 3 . It is noteworthy that the newly identified KLB variant was associated with fecal BA, in view of the role played by the KLB-FGFR4 receptor proteins on hepatocyte BA synthesis.
Moreover, when the four SNVs identified by the association with principal components in 16 IBS-D patients were examined in a larger cohort of 633 patients or healthy controls, FGFR4 rs434434 was associated with symptom phenotype (Table 3) , and FGFR4 rs1966265 was possibly associated with colonic transit at 24 h in 141 IBS patients.
We are encouraged that the associations observed are consistent with our prior studies (42) , demonstrating associations of genes for KLB and FGFR4 with IBS phenotype and colonic transit. The most illustrative example is that rs17618244 (Arg728Gln) in KLB is associated with colonic transit at 24 h, and the amino acid change is associated with reduced stability of the KLB protein; dysfunction of the KLB-FGFR4 combined protein complex results in failure of FGF-19 feedback regulation of hepatocyte BA synthesis. Thus, with the KLB genotype variant, greater BA synthesis and excretion would be expected. The interaction of KLB and FGFR4 is complex. For example, there is evidence that KLB may promote FGFR4's activation by specifically binding to dominant negative glycosylated forms of FGFR4 in the endoplasmic reticulum, preferentially mediating their proteasomal degradation to permit FGF-19-mediated signaling through active forms of FGFR4 (33) .
Significance of current exome DNA studies relative to published literature. In the present study, KLB rs17618244 was not associated with the principal component subgroups. Although we had previously shown that the SNV was functionally relevant and associated with colonic transit in IBS-D (42), we confirmed that there was no significant association with IBS symptom phenotype (Tables 4 and 5) in the current cohort of 633 participants, all of whom were included in the previously reported cohort (42) . In addition, as in a prior study (43) , we identified a significant association of rs17618244 and colonic transit at 24 and 48 h.
Variations in KLB and FGFR4 also modified responses to BA-directed therapy (chenodeoxycholic acid and colesevelam, respectively) in IBS-C and IBS-D. The exome in-depth analysis identified other genetic variants, although these are not necessarily functional. In fact, Table 6 shows that the rs434434 SNV is intronic, suggesting that it may not be directly causing a functional change in the protein FGFR4.
On the other hand, two SNVs are nonsynonymous and potentially functional. Perspective on application of deep sequencing of DNA in IBS-D. There is much enthusiasm and hope that next generation, including exome sequencing, will provide diagnostic information through the identification of de novo mutations (23, 35) . However, complex disorders or phenotypes with multiple potential mechanisms will present additional challenges.
We perceive that the approach we have chosen has potential advantages. First, we identify subgroups based on principal components analysis to narrow the spectrum of phenotypes that are explored by the nonselective genome sequencing approach. Second, we focus on the putative genes in a pathway that alters a specific pathophysiological mechanism in the disorder, thereby providing a means to interrogate the role of the pathway and its associated genetic variations without inflating the false detection rate for any SNV. Third, we interrogate a larger cohort of patients using symptom phenotype and quantitative trait (colonic transit) to assess in a larger cohort of patients the potential functional relevance of the SNVs identified in the focused group, relative to ethnically similar controls. Overall, the data from the present in-depth DNA analysis enhance our understanding of mechanisms that are associated with colonic transit, as well as with subgroups of IBS-D patients identified by principal components analysis. Given the multifactorial nature of IBS, and especially IBS-D (6), it is unlikely that a specific genetic predisposition will account for more than a minor component of the variance of the disorder. Further studies of the interaction of stress, parental influence, the environment, and epigenetic modification of the FGFR4 gene may further elucidate the potential role of genetic predisposition in IBS.
Summary and conclusion. In summary, in-depth DNA sequencing identified additional genetic coding and noncoding variants in KLB and FGFR4 that are univariately associated with fecal BA excretion or colonic transit in IBS-D. Deficiency of FGF-19 in patients with IBS-D is not associated with variation in FGF19 gene. These hypothesis-generating data provide additional weight to the rationale to identify and treat alterations of BA kinetics and colonic transit in patients with IBS; indeed, rational treatment may involve modulation of the BA pathway itself with agents such as BA, BA transport inhibitors in IBS-C (e.g., elobixibat), or BA sequestrants (e.g., cholestyramine and colesevelam) in IBS-D.
APPENDIX
All other mutations identified in mining the complete genome in more than one sample during the EXOME DNA analysis are listed in Appendix Table A1 . Note that for the 118 mutations listed here, the HapMap CEU MAF is not available except for ANXA9 rs 267731, whose MAF is 0.017.
Appendix Table A2 lists functions and potential significance of gene variants among 118 SNVs that were identified in mining the complete genome in IBS patients, but not in 50 controls.
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